1. Home
  2. AAME vs GRDX Comparison

AAME vs GRDX Comparison

Compare AAME & GRDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Atlantic American Corporation

AAME

Atlantic American Corporation

N/A

Current Price

$1.31

Market Cap

34.3M

Sector

Finance

ML Signal

N/A

Logo GridAI Technologies Corp.

GRDX

GridAI Technologies Corp.

N/A

Current Price

$3.53

Market Cap

28.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
AAME
GRDX
Founded
1968
N/A
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Life Insurance
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
34.3M
28.6M
IPO Year
1995
2016

Fundamental Metrics

Financial Performance
Metric
AAME
GRDX
Price
$1.31
$3.53
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
17.9K
★ 73.8K
Earning Date
11-13-2026
11-18-2026
Dividend Yield
★ 1.53%
N/A
EPS Growth
N/A
★ 21.95
EPS
★ 0.22
N/A
Revenue
★ $188,227,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$5.91
★ N/A
Revenue Growth
★ 0.77
N/A
52 Week Low
$1.25
$1.87
52 Week High
$3.24
$6.93

Technical Indicators

Market Signals
Indicator
AAME
GRDX
Relative Strength Index (RSI) N/A 57.46
Support Level N/A $2.63
Resistance Level N/A $4.19
Average True Range (ATR) 0.00 0.34
MACD 0.00 0.06
Stochastic Oscillator 0.00 76.73

Price Performance

Historical Comparison
AAME
GRDX

About AAME Atlantic American Corporation

Atlantic American Corp operates in specialty markets within the life and health and property and casualty insurance industries. The company has two segments: American Southern, It provides property and casualty insurance including bodily injury and property damage liability coverage, uninsured motorist coverage, and physical damage coverage for commercial accounts, and Bankers Fidelity, the company's life and health operations offer a variety of life and supplemental health products including ordinary and term life insurance, Medicare supplement, and other health insurance.

About GRDX GridAI Technologies Corp.

GridAI Technologies Corp, formerly known as Entero Therapeutics Inc, is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.

Share on Social Networks: